Advances and Perspectives in methods for identifying high platelet reactivity.

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Antiplatelet therapy is essential for preventing ischemic events in cardiovascular and cerebrovascular diseases.
• Poor response to P2Y12 inhibitors poses a significant risk of thrombosis, complicating treatment selection.
• Commonly used P2Y12 inhibitors include clopidogrel, ticagrelor, and prasugrel.

Purpose of the Study:

• To review and analyze methods for predicting high platelet reactivity to P2Y12 inhibitors.
• To guide the rational clinical application of P2Y12 receptor inhibitors based on patient-specific risk factors.
• To avert major adverse cardiovascular and cerebrovascular events (MACCE) through personalized antiplatelet therapy.

Main Methods:

• Summarization of existing identification methods for predicting platelet reactivity.
• Analysis of the advantages and drawbacks of different prediction methods in clinical settings.
• Evaluation of genetic testing, platelet function testing, and risk scores.

Main Results:

• Various methods exist to predict platelet reactivity and P2Y12 inhibitor response.
• Each method (genetic, functional, risk scores) has unique strengths and limitations for clinical use.
• Predictive assessment is key to optimizing antiplatelet therapy and reducing MACCE.

Conclusions:

• Accurate prediction of P2Y12 inhibitor response is vital for effective antiplatelet therapy.
• Understanding the pros and cons of different predictive methods aids clinical decision-making.
• Personalized selection of P2Y12 inhibitors can improve patient outcomes and reduce thrombotic risks.